Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
Provided drugs are underlined
For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079
COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Age - Patients must be greater than or equal to 3 years and less than 22 years at the time of planned enrollment on ACNS1422.
COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients. Patients age > 3 and < 22 years at the time of diagnosis. - TEMPORARY CLOSURE
COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years. Patients > 12 months and < 21 years of age.
COG ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT). Patients must be ≥ 3 years and ≤ 21 years of age. TEMPORARY CLOSURE
COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study.
COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.
COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be < 30 years old at the time of diagnosis.
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Age:
COG-AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Patients must be ≥1 year and < 22 years of age at the time of enrollment.
COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Age - Patients ≥1 year and < 31 years of age at the time of relapse will be eligible.
COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. TEMPORARY CLOSURE
COG-AALL05B1: Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens. Age <31 years of age at the time of initial diagnosis of ALL.
COG AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). < 31 years of age at diagnosis of acute leukemia.
COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations - PARTIAL CLOSURE
Patients must be > 365 days and < 31 years of age
COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. TEMPORARY CLOSURE
COG ANHL12P1: A Randomized Phase 2 study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117.
Patient must be < 22 years of age.
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Age:
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.
COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.
COG ALTE05N1: Umbrella Long-term Follow-up Protocol. Only available to patients already enrolled on a COG intervention protocol.
COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study.
COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Patients ≤ 50 years of age at enrollment will be eligible for this study.
COG ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Patients must be ≥ 2 years at the time of the biopsy that established the diagnosis of NRSTS will be eligible
COG-AOST1321: Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma - TEMPORARY CLOSURE
Patients must be equal to or greater than 11 years of age but less than 50 years of age at the time of enrollment.
COG-ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Feasibility Phase: Patients must be < 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≤ 40 years of age at the time of enrollment.
COG AOST1421: A Phase 2 Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma TEMPORARY CLOSURE
Patients must be less than 30 years of age at enrollment.
Copyright 2018. Cancer Research Consortium of West Michigan (CRCWM). All rights reserved.